“For decades, researchers have searched for gerotherapeutic drugs—ones that slow the biological process of aging rather than target specific disease pathways—with little progress. But in recent years, GLP-1 drugs like Ozempic and Wegovy have started to make researchers rethink what an anti-aging drug might look like.
These drugs were developed to lower blood sugar, but their benefits appear to extend well beyond diabetes and weight loss. Studies have linked GLP-1s to improvements in cardiovascular and kidney disease, and early research suggests they may also affect mild cognitive impairment, chronic inflammation, immune function, and some measures of epigenetic aging.”
“As the list of potential benefits has grown, it has caught geroscientists’ attention. They are now investigating whether these drugs treat several age-related conditions separately—or act on something those conditions share.A new study in Nature has added to that possibility. Researchers found that semaglutide—the active ingredient in Ozempic and Wegovy—slowed several signs of aging and extended lifespan in healthy older mice. The results do not demonstrate that GLP-1 drugs slow aging in people. But the findings have made one question more urgent: Could GLP-1 drugs do more than treat age-related diseases—and actually slow aging?”